RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Neuro, From your experience with other small bio companies, I was wondering how often microcaps tend to do a shelf vrs the regular PIPE approach? I've seen numerous larger companies go the shelf route, and I assumed there must have been some barrier to tiny companies doing it. Thanks Neuro.

Well, the market response to the shelf looks pretty bad. I was surprised at the size of it, thought as you said, Stoll can just do a portion at a time. That flexibility could be a significant advantage to Cortex, though on the other hand Wall St may just figure that Cortex will quickly issue additional portions from the shelf if/when the stock moves up, so that creates a big potential overhang to mute any future up moves.

I figured this financing situation would get ugly. Once the stock finally bottoms though, the bigger question is our path forward for CX-717 - does it have a future for outlicensing. Objectively, I've basically written off ADHD, but AD might still be viable depending on the extent of the dosing liberalization. Even without CX-717, the N.Amer Neurodegenerative rights still represent value to Organon, though it would be a shame to lose that last remaining prize during a period of financial desperation. Ah, the joys of biotech...